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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S226Biopress Flexercell plates (1.7 MPa, 1Htz during 24h). Conditioned
media from compressed (CM) or uncompressed (UCM) osteoblasts were
used to stimulate mouse articular chondrocytes. Then, soluble media-
tors released by compressed osteoblasts were identiﬁed by iTRAQ,
a differential secretomic analysis approach. Chondrocyte expression of
matrix metalloproteinase 3 (MMP-3) and MMP-13, tissue inhibitors of
metalloproteinases (TIMPs), and cartilage extracellular matrix compo-
nents type II collagen and aggrecan were assessed by RT-PCR, western
blot analysis and ELISA. Immunodepletion and blocking antibody
experiments were realized using mouse compressed conditioned
media. Human experiments: OA tissue was obtained from patients
undergoing total knee replacement. Subchondral bone and cartilage
from tibial plateaus and femoral condyles were isolated, cut into small
pieces, washed and incubated in culture medium. Conditioned media
were then collected, centrifuged and used to stimulate human articular
chondrocytes.
Results: Media from compressed osteoblast (CM) strongly induced
MMP-3 and -13 chondrocyte mRNA expression. Consistently, CM oste-
oblasts-derived media also signiﬁcantly stimulated the releases of
MMP-3 and -13 by chondrocytes. CM osteoblasts-derived media also
affected cartilagematrix proteins expressions by downregulating type II
collagen mRNA. Effects of CM osteoblasts-derived media on cytosolic
type II collagen protein amounts were conﬁrmed by western blot. So,
the ability of soluble mediators released by loaded osteoblasts to induce
a chondrocyte pro-catabolic phenotype was demonstrated.
In order to identify osteoblast-derived soluble mediators responsible
for this chondrocyte phenotype, osteoblast-derived conditioned media
were analyzed by iTRAQ. This sophisticated proteomic technique
allowed identiﬁcation of 105 proteins secreted by osteoblasts among
which only 10% were upregulated in response to compression. Among
them, secreted 14-3-3ε (s14-3-3 ε) dose-dependently induced the
release of pro-catabolic factors (MMP-3, MMP-13) by mouse chon-
drocytes. s14-3-3ε dramatically mimicked the effects of CM osteoblasts-
derived media. MMP-3 and MMP-13 chondrocyte expressions were
strongly inhibited by a s14-3-3 blocking antibody or by immunode-
pleting s14-3-3 when added into the CM osteoblasts-derived media.
Furthermore, s14-3-3εwas strongly released by human OA subchondral
bone and paralleled with the increase of MMP-3 expression in these
human samples. MMP-3 expression was dose dependently stimulated
by recombinant s14-3-3ε in human OA chondrocytes.
Conclusions: We have identiﬁed s14-3-3ε as a novel soluble mediator,
critical in the communication between subchondral bone and cartilage,
that opens new perspectives in the ﬁelds of biomarkers and ther-
apeutical targets in osteoarthritis.
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WNT5A/CAMKII PATHWAY IS ACTIVATED IN OSTEOARTHRITIS AND
PROMOTES LOSS OF CHONDROCYTE PHENOTYPE
G. Nalesso y, B.L. Thomas y, S.E. Eldridge y, K. Wagner y, J. Sherwood z, J.
Bertrand z, T. Pap z, C. Pitzalis y, F. Dell'Accio y. yWilliam Harvey Res.
Inst., London, United Kingdom; z Inst. für Experimentelle
Muskuloskelettale Medizin, Muenster, Germany
Purpose of the study: Disruption of Wnt signalling results in osteoar-
thritis both in humans and experimental models. However, the role of
Wnt pathways in the pathogenesis of this disease has not been fully
characterized yet. We have recently demonstrated that Wnt-dependent
activation of the Calcium Calmodulin Kinase II (CaMKII) is detrimental
for the maintenance of articular chondrocyte homeostasis in vitro
(Nalesso et al., JCB 2011). The aim of this study was then to determine
the role of the Wnt/CaMKII pathway in human articular cartilage and in
the development of osteoarthritis.
Methods: Cartilage explants were removed from the knees of patients
undergone joint replacement for osteoarthritis. Osteoarthritis was
induced in 8 weeks old 129/Sv mice by destabilization of the medial
meniscus (DMM) and the mice were sacriﬁced 8 weeks post-surgery.
The expression level of the different CaMKII isoforms in articular
cartilage was evaluated by PCR and immunohistochemistry. CaMKII
phosphorylation was assessed by immunoﬂuorescence. Articular
chondrocytes were isolated by enzymatic digestion from the metatarsal
joint of a bovine hoof obtained from a local abattoir. The chondrocytes
were stimulated with recombinant Wnt5a in presence/absence of
KN93, a CaMKII inhibitor. Calciummobilization was detected by cellular
accumulation of FURA-2 dye and phosphorylation of CaMKII by
Western blotting analysis. Gene expression analysis of chondrocytemarkers including Col2A1, Aggrecan and Sox9, was performed by
quantitative real time PCR.
Results: Only CaMKIIg and -d were expressed in human and murine
articular cartilage. Phospho-CaMKII (pCaMKII), the activated form of
CaMKII, was expressed only in the cartilage of osteoarthritic patients
and was totally absent in normal cartilage. pCaMKII was also signiﬁ-
cantly upregulated in mice upon DMM in comparison with the
contralateral sham-operated joint. The expression of Wnt5a, known to
modulate the CaMKII pathway in different biological systems, was up-
regulated in OA samples. Wnt5a stimulation promoted calcium mobi-
lization and CaMKII phosphorylation in articular chondrocytes. Wnt5a
induced loss of chondrocyte phenotype which was rescued by CaMKII
inhibition.
Conclusions: These results showed that activation of the Wnt5a/
CaMKII pathway correlates with the development of osteoarthritis both
in human and in animal models. CaMKII blockade rescued the loss of
chondrocyte phenotype induced by Wnt5a in articular chondrocytes,
therefore suggesting that the inhibition of this signalling cascade might
represent a new therapeutic strategy useful to tackle the development/
progression of osteoarthritis.
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ANNEXIN A6: A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT
OF OSTEOARTHRITIS?
T. Kirsch, T. Minashima, K. Campbell, Y. Zhang. NYU Sch. of Med.,
New York, NY, USA
Purpose: NF-kb and Wnt/b-catenin signaling are two major pathways
involved in osteoarthritis (OA). Members of the annexin protein family
have been implicated to play essential roles in various disease pathol-
ogies based on their function tomodulate signaling pathways, including
NF-kB. Based on these ﬁndings and our ﬁndings showing that annexin
A6 (AnxA6) is highly expressed in OA cartilage but not in normal
healthy articular cartilage, we hypothesized that AnxA6 is a major
contributor to cartilage destruction during OA.
Methods: The expression of catabolic genes and the activation of NF-kB
and Wnt/b-catenin signaling in articular chondrocytes isolated from
AnxA6 knockout (-/-) and wild type (WT) mice and in human articular
chondrocytes overexpressing AnxA6 and cultured in the absence or
presence of interleukin (IL)-1 and Wnt3a were determined by real time
PCR and luciferase reporter assays. IL-1 injections into the knee joints of
AnxA6-/- and WT mice were used to determine the role of AnxA6 in IL-
1-mediated cartilage destruction. The mechanism of how AnxA6
stimulates NF-kB and Wnt/b-catenin signaling was determined by co-
immunoprecipitation and immunoblot analysis of plasma membrane,
nuclear and cytoplasmic fractions of IL-1 or Wnt3a-treated AnxA6-/-
and WT chondrocytes. Cartilage degradation in an OA mouse model
using the transection of the medial collateral ligament and partial
medial meniscetomy (PMX) was analyzed histologically by safranin O
staining.
Results: Lack of AnxA6 in articular chondrocytes isolated from AnxA6-/-
mice resulted in decreased NF-kB activity after IL- 1 treatment and
increased Wnt/b-catenin signaling after Wnt3a treatment. Over-
expression of AnxA6 in human articular chondrocytes was sufﬁcient for
a marked increase in NF-kB activity and decreased Wnt/b-catenin
signaling activity. AnxA6 interaction with p65 resulted in increased
nuclear translocation and retention of the active p50/p65 NF-kB
complex, whereas plasmamembrane-associated AnxA6 interfered with
the membrane-association of the Wnt signalosome complex required
for the activation of Wnt/b-catenin signaling. IL-1 treatment resulted in
a markedly reduced increase of the mRNA levels of catabolic markers,
including ADAMTS-5, IL-6, iNOS, and MMP-13, in AnxA6-/- chon-
drocytes compared with IL-1-treated WT chondrocytes, whereas over-
expression of AnxA6 resulted in increased mRNA levels of these
catabolic markers in the absence or presence of IL-1. Intraarticular
injections of IL-1 into the knee joints of AnxA6-/- mice resulted in
decreased proteoglycan loss, cartilage degradation, and MMP-13
expression compared with Il-1 injections intoWT knee joints. Contrary,
cartilage degradation in the PMX-induced post-traumatic OA model, in
which the Wnt/b-catenin signaling plays a major role in mediating
cartilage degradation, was markedly accelerated in AnxA6-/- mice
compared toWTmice. Finally, we provide evidence that Wnt/b-catenin
signaling in human articular chondrocytes inhibited catabolic events,
especially NF-kB-mediated catabolic events, whereas inmouse articular
chondrocytes Wnt/b-catenin signaling stimulated catabolic events.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S227Conclusions: Our ﬁndings show that (a) Wnt/b-catenin signaling acts
anti-catabolic in human articular chondrocytes and especially inhibits
NF-kB-mediated catabolic events, whereas Wnt/b-catenin signaling in
mouse articular chondrocytes stimulates catabolic events, and that (b)
AnxA6 via stimulating NF-kB activity and inhibiting Wnt/b-catenin
signaling plays a major role in human cartilage degradation during OA
pathology. Our ﬁndings suggest that targeting AnxA6 function, espe-
cially its modulatory function of the NF-kB andWnt/b-catenin signaling
pathways may be a more effective way to control these signaling
pathways and their interactions during OA pathology than targeting
these individual pathways directly.
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CONTRAST-BASED MICRO-CT ANALYSIS OF MMP INHIBITOR
EFFICACY IN A RAT OSTEOARTHRITIS MODEL
T. Thote y, N.J. Willett y, M.A. Hart z, A.S. Lin y, S. Moran y, R.E.
Guldberg y, R.V. Kamath z. yGeorgia Inst. of Technology, Atlanta, GA,
USA; zAbbott Lab., Worcester, MA, USA
Purpose: Osteoarthritis (OA) is the most common degenerative joint
disease in humans and there are currently no clinically viable disease
modifying osteoarthritis drugs (DMOADs). Previous studies have tested
matrix metalloproteinase inhibitors (MMPis) in different animal models
and demonstrated efﬁcacy. In these studies, histopathology analysis has
been used as the traditional method to evaluate efﬁcacy of MMPi's. This
technique is time consuming, 2D, requires large samples sizes and
semi–quantitative. Equilibrium Partitioning of an Ionic Contrast Agent
based micro-CT (EPIC-mCT) imaging can be used to nondestructively
quantify changes in articular cartilage but has not previously been
applied to evaluate the efﬁcacy of DMOADs. Objective: Evaluate the
efﬁcacy of a broad spectrum MMPi (ABT-518 from Abbott Laboratories,
Abbott Park, IL) in the rat medial meniscal tear (MMT) model using
EPIC-mCT based quantitative parameters. Hypothesis: EPIC-mCT
provides a sensitive method to detect therapeutic effects of MMP
inhibition in a rat OA model.
Methods: Animal model: Weight matched male Lewis rats (275-300g)
were separated in three groups: Sham surgery, MMT +MMPi (30 mg/kg
orally twice a day for 21 days) and MMT+ vehicle (n¼14-15). All
surgeries were performed at Abbott Laboratories and approved by the
IACUC. m-CT Imaging: Joints were dissected and scanned following
equilibration in Hexabrix contrast agent. Images were evaluated for 3
volumes of interest (VOIs): (1) Only osteophytes (2) Medial 1/3 region of
medial tibial plateau cartilage (3) Only focal cartilage lesions (defect >
50% of cartilage thickness) on the medial plateau. Statistics: Data are
shown as means  SEM and analyzed via t-test or one-way ANOVA
(GraphPad Prism5 Software)
Results: Osteophyte: Representative coronal grayscale CT images show
the osteophytes in the vehicle MMT group compared to the MMPi
treated and sham group (Fig 1).
Figure 1. Delineation of osteophyte (OP) and representative images from experimental
groups.Quantitative EPIC-mCT showed signiﬁcantly higher total periph-
eral volume, mineralized peripheral volume, cartilaginous peripheral
volume and average 3D peripheral thickness in the vehicle MMT group
compared to MMPi treated group (Fig 2). No evidence of osteophytes
was observed in the sham animals. Cartilage: Representative imagesshow delineation of the medial 1/3 tibial plateau from the medial tibial
plateau and illustration of lesion vs. erosion sites (Fig 3 A, B). Cartilage
volume increased at 3 weeks in the vehicle MMT and MMPi treated
groups compared to the shams (Fig 3C). Lesion volumewas signiﬁcantly
lower in the MMPi group compared to the vehicle MMT group (Fig 3D).
The shams showed no lesions on the articular surface.
Figure 2. Quantiﬁcation of osteophyte parameters.Ă
Figure 3. Evaluation of medial 1/3 cartilage volume and lesion volume.ĂPower
analysis: A power analysis was performed to measure the minimum
number of samples required to detect differences in osteophyte
development between theMMPi treated and vehicle MMTgroups. Post-
hoc power analysis based on total peripheral volume indicated that
a minimum of 5 animals would be needed per group to detect
a signiﬁcant difference at a power > 0.8 and a ¼ .05.
Conclusions: In summary, 3D image analyses of retrieved joints indi-
cated that MMPi reduces focal lesion volume and osteophyte develop-
ment. Power analyses showed that the effects of the MMPi treatment
could be detected with as few as 5 samples per group when using EPIC-
mCT. This is the ﬁrst study to demonstrate the use of EPIC-mCTas a tool to
study efﬁcacy of potential DMOADs in rat MMT model of OA.
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BISPHOSPHONATE USE REDUCES PAIN AND RADIOLOGICAL
PROGRESSION IN PATIENTS WITH SYMPTOMATIC AND
RADIOGRAPHIC KNEE OSTEOARTHRITIS: DATA FROM THE
OSTEOARTHRITIS INITIATIVE
L.L. Laslett y, S.R. Kingsbury y, E.M. Hensor y, M.A. Bowes z, P.G.
Conaghan y. yUniv. of Leeds, Leeds, United Kingdom; z Imorphics Ltd,
Manchester, United Kingdom
Background: Bisphosphonate use has been studied in patients with OA,
with apparent mixed results. Effects on bone have generally been
positive: an observational study reported a 90% reduction in odds of
having a bone marrow lesion (BML) with the use of alendronate (OR
0.11, p0.05), whilst risedronate (50mg weekly) prevented an increase
in BML size over 24 months although this did not reach statistical
signiﬁcance. Risedronate (15 mg) reduced markers of cartilage
